Advertisement

Topics

AML drug candidate secures $3.2 million in funding

04:37 EDT 11 Aug 2017 | SmartBrief

The Leukemia & Lymphoma Society of Rye Brook will provide Poland-based Selvita S.A.  -More

Original Article: AML drug candidate secures $3.2 million in funding

NEXT ARTICLE

More From BioPortfolio on "AML drug candidate secures $3.2 million in funding"

Quick Search
Advertisement
 

Relevant Topic

Leukemia
Leukemia is a type of cancer of the blood or bone marrow characterized by an abnormal increase of immature white blood cells called "blasts". Leukemia is a broad term covering a spectrum of diseases. In turn, it is part of the even broader grou...